

PRESS RELEASE

02 April 2025 12:18:00 CEST

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Saniona announces preliminary outcome of exercise of warrants series TO 4

The exercise period for warrants series TO 4 ("TO 4") in Saniona AB ("Saniona" or the "Company") ended on 1 April 2025. The preliminary outcome indicates that a total of 22,987,797 warrants were exercised for subscription of 22,987,797 new shares for approximately SEK 112 million, corresponding to an exercise rate of approximately 97.6 percent. The preliminary outcome thus indicates that the top-down guarantee commitments that the Company has entered into will be executed with approximately SEK 3 million, corresponding to approximately 2.4 percent of the total number of TO 4, resulting in TO 4 being exercised up to 100 percent, corresponding to a total of approximately SEK 115 million. The final outcome and additional information on the execution of the top-down guarantee commitments will be published in a separate press release.

The exercise period for TO 4 took place during the period 18 March – 1 April 2025. One (1) TO 4 entitled the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 4.88 per share. The preliminary outcome indicates that a total of 22,987,797 warrants were exercised for subscription of 22,987,797 new shares for approximately SEK 112 million, corresponding to an exercise rate of approximately 97.6 percent. The preliminary outcome thus indicates that the top-down guarantee commitments that the Company has entered into will be executed with approximately SEK 3 million, corresponding to approximately 2.4 percent of the total number of TO 4, resulting in TO 4 being exercised up to 100 percent, corresponding to a total of approximately SEK 115 million.

The final outcome and additional information on the execution of the top-down guarantee commitments will be published in a separate press release which is expected to be announced on 3 April 2025.

Advisers

Vator Securities AB is financial adviser and Setterwalls Advokatbyrå AB is legal adviser to the Company in connection with the exercise of TO 4. Vator Securities AB is also issuing agent in connection with the exercise of TO 4.

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Saniona. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Saniona has only been made through the prospectus published by Saniona on 18 January 2024. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, www.saniona.com.

Since Saniona is considered to conduct protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of shares may require review by the Inspectorate of Strategic Products (ISP). More information about this can be found on the Company's website, www.saniona.com.

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: Tesomet™, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona's partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.

For more information, visit www.saniona.com.

This information is information that Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-02 12:18 CEST.

Attachments

Saniona announces preliminary outcome of exercise of warrants series TO 4